Annual Operating Expenses
$189.33 M
-$27.09 M-12.52%
September 30, 2024
Summary
- As of February 26, 2025, ENTA annual total operating expenses is $189.33 million, with the most recent change of -$27.09 million (-12.52%) on September 30, 2024.
- During the last 3 years, ENTA annual operating expenses has fallen by -$17.32 million (-8.38%).
- ENTA annual operating expenses is now -12.52% below its all-time high of $216.41 million, reached on September 30, 2023.
Performance
ENTA Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$40.50 M
-$3.96 M-8.90%
December 31, 2024
Summary
- As of February 26, 2025, ENTA quarterly total operating expenses is $40.50 million, with the most recent change of -$3.96 million (-8.90%) on December 31, 2024.
- Over the past year, ENTA quarterly operating expenses has stayed the same.
- ENTA quarterly operating expenses is now -30.24% below its all-time high of $58.06 million, reached on December 31, 2021.
Performance
ENTA Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
ENTA Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -12.5% | 0.0% |
| 3 y3 years | -8.4% | -22.1% |
| 5 y5 years | +12.4% | -29.3% |
ENTA Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -12.5% | at low | -30.2% | at low |
| 5 y | 5-year | -12.5% | +15.4% | -30.2% | +2.5% |
| alltime | all time | -12.5% | +1096.7% | -30.2% | +932.4% |
Enanta Pharmaceuticals Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $40.50 M(-8.9%) |
| Sep 2024 | $189.33 M(-12.5%) | $44.46 M(+5.5%) |
| Jun 2024 | - | $42.16 M(-15.4%) |
| Mar 2024 | - | $49.82 M(-5.8%) |
| Dec 2023 | - | $52.89 M(+5.9%) |
| Sep 2023 | $216.41 M(+3.1%) | $49.96 M(-10.1%) |
| Jun 2023 | - | $55.60 M(-2.9%) |
| Mar 2023 | - | $57.25 M(+6.8%) |
| Dec 2022 | - | $53.60 M(+13.2%) |
| Sep 2022 | $210.00 M(+1.6%) | $47.37 M(-8.9%) |
| Jun 2022 | - | $52.02 M(-1.0%) |
| Mar 2022 | - | $52.56 M(-9.5%) |
| Dec 2021 | - | $58.06 M(+1.3%) |
| Sep 2021 | $206.65 M(+25.9%) | $57.30 M(+3.3%) |
| Jun 2021 | - | $55.47 M(+11.3%) |
| Mar 2021 | - | $49.83 M(+13.1%) |
| Dec 2020 | - | $44.04 M(+1.4%) |
| Sep 2020 | $164.11 M(-2.6%) | $43.41 M(+4.6%) |
| Jun 2020 | - | $41.51 M(+5.1%) |
| Mar 2020 | - | $39.49 M(-0.5%) |
| Dec 2019 | - | $39.70 M(-11.5%) |
| Sep 2019 | $168.46 M(+42.4%) | $44.88 M(+10.5%) |
| Jun 2019 | - | $40.61 M(-0.8%) |
| Mar 2019 | - | $40.94 M(-2.6%) |
| Dec 2018 | - | $42.03 M(+28.3%) |
| Sep 2018 | $118.30 M | $32.75 M(-5.4%) |
| Jun 2018 | - | $34.62 M(+27.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $27.19 M(+14.6%) |
| Dec 2017 | - | $23.73 M(+9.7%) |
| Sep 2017 | $78.20 M(+36.2%) | $21.63 M(+4.8%) |
| Jun 2017 | - | $20.64 M(+11.8%) |
| Mar 2017 | - | $18.46 M(+5.7%) |
| Dec 2016 | - | $17.46 M(+9.6%) |
| Sep 2016 | $57.43 M(+56.3%) | $15.94 M(+5.8%) |
| Jun 2016 | - | $15.07 M(+11.0%) |
| Mar 2016 | - | $13.57 M(+5.6%) |
| Dec 2015 | - | $12.85 M(+19.6%) |
| Sep 2015 | $36.73 M(+27.7%) | $10.74 M(+8.5%) |
| Jun 2015 | - | $9.90 M(+12.4%) |
| Mar 2015 | - | $8.81 M(+20.8%) |
| Dec 2014 | - | $7.29 M(-8.5%) |
| Sep 2014 | $28.76 M(+24.9%) | $7.96 M(+11.3%) |
| Jun 2014 | - | $7.16 M(-1.8%) |
| Mar 2014 | - | $7.29 M(+14.8%) |
| Dec 2013 | - | $6.35 M(+5.0%) |
| Sep 2013 | $23.02 M(+12.8%) | $6.05 M(+3.8%) |
| Jun 2013 | - | $5.83 M(+12.1%) |
| Mar 2013 | - | $5.20 M(-12.7%) |
| Dec 2012 | - | $5.95 M(-0.1%) |
| Sep 2012 | $20.42 M(+23.1%) | $5.95 M(-1.9%) |
| Jun 2012 | - | $6.07 M(+35.8%) |
| Mar 2012 | - | $4.47 M(+13.9%) |
| Dec 2011 | - | $3.92 M(-5.0%) |
| Sep 2011 | $16.58 M(+4.8%) | $4.13 M |
| Sep 2010 | $15.82 M | - |
FAQ
- What is Enanta Pharmaceuticals annual total operating expenses?
- What is the all time high annual operating expenses for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals annual operating expenses year-on-year change?
- What is Enanta Pharmaceuticals quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly operating expenses year-on-year change?
What is Enanta Pharmaceuticals annual total operating expenses?
The current annual operating expenses of ENTA is $189.33 M
What is the all time high annual operating expenses for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high annual total operating expenses is $216.41 M
What is Enanta Pharmaceuticals annual operating expenses year-on-year change?
Over the past year, ENTA annual total operating expenses has changed by -$27.09 M (-12.52%)
What is Enanta Pharmaceuticals quarterly total operating expenses?
The current quarterly operating expenses of ENTA is $40.50 M
What is the all time high quarterly operating expenses for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high quarterly total operating expenses is $58.06 M
What is Enanta Pharmaceuticals quarterly operating expenses year-on-year change?
Over the past year, ENTA quarterly total operating expenses has changed by $0.00 (0.00%)